Pharmacogenomic Testing: Clinical Trials

9 trials of Pharmacogenomic Testing, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 unknown, 2 active not recruiting, 1 terminated. 9 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 3, Unknown 3, Active not recruiting 2, Terminated 1
Phase 21Terminated 1

Follow Pharmacogenomic Testing: new trials by email Literature Review of Pharmacogenomic Testing trials Research Report on Pharmacogenomic Testing

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacogenetics in Primary Care Psychotropics
Pharmacogenetic testing - Depression, Obsessive-Compulsive Disorder
Phase 3UnknownUniversity of Arizona1302017-08-152017-07-28
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Phase 3Active not recruitingNational Cancer Institute (NCI)942016-10-122026-11-13
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Cyclophosphamide, Fludarabine Phosphate, Ibrutinib - Anemia, Chronic Lymphocytic Leukemia
Phase 3Active not recruitingNational Cancer Institute (NCI)5292014-03-102026-08-28
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
pazopanib hydrochloride, laboratory biomarker analysis, pharmacogenomic studies - Lung Cancer
Phase 2 / Phase 3TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC1022011-07-012018-07-12
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Pharmacogenetic, Target INR 1.8 - Thromboembolism
Phase 3CompletedWashington University School of Medicine15982011-03-012016-12-29
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
doxorubicin-eluting beads, sorafenib tosylate, laboratory biomarker analysis - Liver Cancer
Phase 3UnknownUniversity College, London4122010-11-012011-05-13
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study - Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Phase 3CompletedNational Cancer Institute (NCI)3562010-02-152026-06-24
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer
Phase 3UnknownUniversity of Glasgow2142009-04-012011-05-13
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
gemcitabine hydrochloride, bevacizumab, placebo - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Phase 3CompletedNational Cancer Institute (NCI)5902004-06-012013-06-05

Conditions studied

Carcinoma, Hepatocellular (2)  ·  Depression (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Adenocarcinoma of Lung (1)  ·  Adenocarcinoma, Bronchiolo-Alveolar (1)  ·  Anemia (1)  ·  Anxiety Disorders (1)  ·  Blast Crisis (1)  ·  Burkitt Lymphoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Congenital Abnormalities (1)  ·  Generalized Anxiety Disorder (1)  ·  Hodgkin Disease (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Immunoglobulin Light-chain Amyloidosis (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  University College, London (1)  ·  University of Arizona (1)  ·  University of Glasgow (1)  ·  Washington University School of Medicine (1)

Countries

United States (5)  ·  United Kingdom (3)  ·  Belgium (1)  ·  Canada (1)  ·  Egypt (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Netherlands (1)  ·  Puerto Rico (1)  ·  Saudi Arabia (1)  ·  Slovenia (1)

Top investigators

Barry J.A. Laird, MD (1)  ·  Brian F Gage, MD, MSc (1)  ·  Charalambos B Andreadis (1)  ·  Ghassan K Abou-Alfa (1)  ·  Hedy Kindler (1)  ·  Marie T. Fallon (1)  ·  Mary O'Brien, MD (1)  ·  Tait D Shanafelt (1)  ·  Tim Meyer, MD, BSc, MRCP, PhD (1)

Results publications

PMID 28973620, PMID 31365801, PMID 31479138, PMID 31486832, PMID 33439748, PMID 34028627, PMID 34616010, PMID 34865212, PMID 35427411, PMID 35484400, PMID 37801678

NIH funding

U10CA031946 (2), U10CA180821 (2), R01CA193541 (1), R01HL097036 (1), U10CA021115 (1), U10CA180820 (1), U24CA196172 (1)